Australia's most trusted
source of pharma news
Monday, 06 May 2024
Posted 24 April 2024 AM
ASX-listed consumer healthcare company Wellnex Life has officially started the process for a dual listing on the London Stock Exchange (LSE), aligning with the company's international growth strategy.
Wellnex has an existing supply agreement with Haleon in the UK and United Arab Emirates markets and says it is working on "further opportunities both with Haleon and other partners".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.